feedback

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit
Released: December 29, 2017
Expires: December 29, 2018
15 minutes to complete

Accredited By

The University of Nebraska Medical Center, Center for Continuing Education

Provider

This activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend

  

Target Audience

The target audience for this activity is community and academic medical oncologists, advanced practitioners, and other clinicians who treat patients with breast cancer.

Learning Objectives

  • Review the current therapeutic landscape of HR+/HER2- breast cancer
  • Evaluate recently released clinical trial data of current and emerging agents undergoing examination in patients with HR+/HER2- breast cancer
  • Discuss how recently released clinical trial data can be integrated into the treatment armamentarium
  • Develop strategies for the individualized treatment of patients with breast cancer based on efficacy and safety data, as well as patient and disease characteristics

Activity Description

Podium to Practice is an interview involving 2 world renowned experts actively engaged in treatment of patients with breast cancer. They provide expert summary and interpretation of data presented during the 2017 breast cancer conference in San Antonio, as well as provide guidance on the optimal use of current and emerging therapies.

Statement of Educational Need

Due to the volume of research in the treatment of breast cancer, clinicians are challenged to evaluate and interpret the clinical significance of emerging data, both scientific and clinical. Clinicians need expert guidance to assess the benefits of agents for HR+/HER2- breast cancer, to use existing and novel ones safely and effectively, and to plan for optimal integration of new ones as they become available.

Agenda

  • Introduction
  • Current approaches to the care of HR+/HER2- advanced breast cancer
  • MONALESSA-7, Abstract GS2-05
  • neoMONARCH, Abstract PD5-01
  • ABCSG-16, Abstract GS3-01
  • TEXT and SOFT, Abstracts GS4-02 and GS4-03
  • Points to Ponder

Moderator

Mathew N. Beshara, MD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

No financial relationships to disclose


Faculty

Sara A. Hurvitz, MD
Associate Professor, Division of Hematology-Oncology, Department of Medicine
David Geffen School of Medicine at UCLA
Co-Director, Santa Monica-UCLA Outpatient Oncology Practice
Medical Director, Clinical Research
UCLA Jonsson Comprehensive Cancer Center
Director, Breast Oncology Program
Division of Hematology-Oncology, UCLA
Los Angeles, California

Grants/Research Support: Amgen Inc., Bayer Healthcare Pharmaceuticals LLC, BioMarin, Boehringer Ingelheim, Cascadian Therapeutics, Dignitana AB, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline plc, Merrimack, Medivation, Inc., Novartis, OBI Pharma, Inc., Pfizer Inc, Puma Biotechnology, Inc, Seattle Genetics, Inc.

Other: Bayer Healthcare Pharmaceuticals LLC, Eli Lilly and Company, Novartis, OBI Pharma, Inc.


Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Grants/Research Support: Eisai Co., Ltd, Eli Lilly and Company, Genentech/Roche, OBI Pharma, Inc., Pfizer Inc, Plexxikon, Merck & Co., Inc, Novartis


Conflict of Interest Policy/Disclosure Statement

As a provider accredited by ACCME, the University of Nebraska Medical Center (UNMC), Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.

All presenters, planners, and others in a position to control continuing medical education content participating in a UNMC, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the UNMC, Center for Continuing Education.

The following indicates the disclosure declaration information and the nature of those commercial relationships.

All disclosed conflicts of interest have been resolved by independent content review.

Accreditation Statement

The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.

Instructions for Receiving Credit

There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-test and evaluation. Participants who complete the educational activity, pre-/post-test and evaluation will receive a certificate of credit.

Statement of Commercial Support

Educational grant support provided by Novartis.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. UNMC CCE and Bio Ascend do not recommend the use of any agent outside of the labeled indication. The opinions expressed in the educational activity do not necessarily represent the views of UNMC CCE and Bio Ascend. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

University of Nebraska Medical Center, Center for Continuing Education
Brenda Ram, CMP, CHCP
bram@unmc.edu
402-559-9250

Bio Ascend
meetings@bioascend.com

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.